Wolnicka-Glubisz A, Pecio A, Podkowa D, Plonka PM, Grabacka M
This primary search query refers to a combination of three distinct growth hormone secretagogues
Under the reported conditions, AOD9604 reduced body-weight gain in obese mice and was associated with increased whole-body fat oxidation and increased plasma glycerol, which was interpreted as an index of lipolysis
This work has resulted in one accepted manuscript, with another manuscript and a review article currently submitted/under review, and multiple presentations, including one presentation at the national meeting of the American Chemical Society and two accepted abstracts for poster/oral presentations in the near future at ASMS and SERMACS
Liraglutide (Saxenda), an earlier GLP1 medication, uses a similar approach but has a shorter half-life of about 13 hours, requiring daily injection